BR112015012841A2 - composição imunogênica, vacina, e, uso de uma composição imunogênica - Google Patents

composição imunogênica, vacina, e, uso de uma composição imunogênica

Info

Publication number
BR112015012841A2
BR112015012841A2 BR112015012841A BR112015012841A BR112015012841A2 BR 112015012841 A2 BR112015012841 A2 BR 112015012841A2 BR 112015012841 A BR112015012841 A BR 112015012841A BR 112015012841 A BR112015012841 A BR 112015012841A BR 112015012841 A2 BR112015012841 A2 BR 112015012841A2
Authority
BR
Brazil
Prior art keywords
immunogenic composition
vaccine
immunogenic
composition
difficile
Prior art date
Application number
BR112015012841A
Other languages
English (en)
Other versions
BR112015012841B1 (pt
Inventor
Boutriau Dominique
Wallemacq Hugues
Marie Jeanne Valentine Germain Sophie
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112015012841A2 publication Critical patent/BR112015012841A2/pt
Publication of BR112015012841B1 publication Critical patent/BR112015012841B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

1 / 105 1 / 1 resumo “composiã‡ãƒo imunogãšnica, vacina, e, uso de uma composiã‡ãƒo imunogãšnica” a presente invenã§ã£o refere-se a composiã§ãµes imunogãªnicas compreendendo um polipeptã­deo de clostridium difficile (c. difficile) e um adjuvante sem alumã­nio.
BR112015012841-6A 2012-12-05 2013-12-03 Composição imunogênica e uso de uma composição imunogênica BR112015012841B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201221875 2012-12-05
GB1221875.6 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Publications (2)

Publication Number Publication Date
BR112015012841A2 true BR112015012841A2 (pt) 2017-09-26
BR112015012841B1 BR112015012841B1 (pt) 2022-05-03

Family

ID=49724573

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012841-6A BR112015012841B1 (pt) 2012-12-05 2013-12-03 Composição imunogênica e uso de uma composição imunogênica

Country Status (22)

Country Link
US (2) US9694064B2 (pt)
EP (2) EP3513806B1 (pt)
JP (2) JP6290918B2 (pt)
CN (2) CN104884081A (pt)
AR (1) AR093712A1 (pt)
AU (1) AU2013354186A1 (pt)
BR (1) BR112015012841B1 (pt)
CA (1) CA2893435A1 (pt)
CY (1) CY1121560T1 (pt)
DK (2) DK2928489T3 (pt)
ES (2) ES2721930T3 (pt)
FI (1) FI3513806T3 (pt)
HR (2) HRP20230359T1 (pt)
HU (2) HUE061273T2 (pt)
LT (2) LT3513806T (pt)
PL (2) PL3513806T3 (pt)
PT (2) PT2928489T (pt)
SG (1) SG11201503861UA (pt)
SI (2) SI2928489T1 (pt)
TR (1) TR201905272T4 (pt)
WO (1) WO2014086787A1 (pt)
ZA (1) ZA201503927B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101408113B1 (ko) * 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
US9598472B2 (en) 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
SG10201602668VA (en) 2011-04-22 2016-05-30 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN104884081A (zh) * 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
SI3160500T1 (sl) * 2014-06-25 2019-11-29 Glaxosmithkline Biologicals Sa Imunogeni sestavek proti Clostridium difficile
WO2016012587A1 (en) * 2014-07-25 2016-01-28 Biosynth S.R.L. Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
WO2016131157A1 (en) 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2017165398A1 (en) 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
EP4168032A2 (en) * 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JP2851288B2 (ja) 1987-06-05 1999-01-27 アメリカ合衆国 癌診断および管理における自己分泌運動性因子
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
HU219056B (hu) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
BR9509903A (pt) 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP2502998A3 (en) 1999-04-09 2013-02-27 Intercell USA, Inc. Recombinant toxin A/ToxinB vaccine against clostridium difficile
US20020065396A1 (en) 2000-03-28 2002-05-30 Fei Yang Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0525321D0 (en) * 2005-12-13 2006-01-18 Glaxosmithkline Biolog Sa Novel compositions
CN101522218B (zh) * 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
GB0711858D0 (en) 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
RU2550271C2 (ru) 2007-09-14 2015-05-10 Санофи Пастер Байолоджикс Ко. Иммуногенная композиция для лечения или профилактики clostridium difficile, способ ее получения и способ индукции иммунного ответа к c. difficile
KR20110009157A (ko) 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CA2733425A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
US9598472B2 (en) 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
DK3138916T3 (da) 2011-05-27 2019-08-26 Glaxosmithkline Biologicals Sa Immunogen sammensætning
CN104884081A (zh) * 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物

Also Published As

Publication number Publication date
HRP20230359T1 (hr) 2023-06-09
ES2721930T3 (es) 2019-08-06
FI3513806T3 (fi) 2023-04-26
WO2014086787A1 (en) 2014-06-12
CN112807422A (zh) 2021-05-18
PL3513806T3 (pl) 2023-05-15
SI3513806T1 (sl) 2023-04-28
US10130694B2 (en) 2018-11-20
AR093712A1 (es) 2015-06-17
DK3513806T3 (da) 2023-02-27
SI2928489T1 (sl) 2019-05-31
EP2928489B1 (en) 2019-02-27
EP3513806B1 (en) 2023-01-25
TR201905272T4 (tr) 2019-05-21
HUE061273T2 (hu) 2023-06-28
JP6290918B2 (ja) 2018-03-07
LT3513806T (lt) 2023-04-11
LT2928489T (lt) 2019-04-10
EP3513806A1 (en) 2019-07-24
DK2928489T3 (en) 2019-04-23
CY1121560T1 (el) 2020-05-29
PT2928489T (pt) 2019-05-28
BR112015012841B1 (pt) 2022-05-03
CN104884081A (zh) 2015-09-02
CA2893435A1 (en) 2014-06-12
PT3513806T (pt) 2023-03-02
HUE043091T2 (hu) 2019-08-28
JP2016502551A (ja) 2016-01-28
US9694064B2 (en) 2017-07-04
EP2928489A1 (en) 2015-10-14
AU2013354186A1 (en) 2014-06-12
ZA201503927B (en) 2017-11-29
ES2939307T3 (es) 2023-04-20
JP2018104446A (ja) 2018-07-05
PL2928489T3 (pl) 2019-07-31
JP6626521B2 (ja) 2019-12-25
HRP20190711T1 (hr) 2019-05-31
US20150313984A1 (en) 2015-11-05
SG11201503861UA (en) 2015-06-29
US20170340719A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112015012841A2 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
JOP20180102B1 (ar) مركب صيدلاني
BR112014024612A2 (pt) ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
HK1214962A1 (zh) 流感病毒免疫原性組合物及其應用
EP3261668A4 (en) Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2014003308A (es) Vacunas para el virus de la influenza y usos de las mismas.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
EA201590887A1 (ru) Композиция
MX2015008766A (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
MX349119B (es) Vacuna de virus de dengue inactivado.
BR112013030395A2 (pt) polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
AU2011280259A8 (en) Influenza vaccine
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
BR112013024982A8 (pt) Composições de colagem e método de preparação e uso das mesmas
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c
PH12015501099A1 (en) Synbiotic composition and use thereof
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
BR112013019924A8 (pt) Composições para cuidado oral
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
WO2015050950A3 (en) Influenza hemagglutinin variants and uses therefor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2013, OBSERVADAS AS CONDICOES LEGAIS.